today announced the presentation of a trial-in-progress poster on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-catenin TCF4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback